Pfizer Inc. / PowderMed Ltd.

Seasonal and Pandemic Influenza (DNA Vaccines)

43M US cases/yr · $5.0B North America influenza vaccine market 2025 (USD)

Disease Overview

Seasonal influenza causes tens of millions of US illnesses and hundreds of thousands of hospitalizations each year, with elderly, pediatric, and immunocompromised patients carrying disproportionate mortality. Conventional egg-based inactivated vaccines have well-known limitations in speed, strain match, and immunogenicity, fueling interest in DNA-based and needle-free platforms.

Competitive Landscape

At the time of the 2006 acquisition, the seasonal flu vaccine market was dominated by egg-based inactivated injectables from Sanofi Pasteur (Fluzone), GSK (Fluarix/FluLaval), Novartis (Fluvirin/Agriflu), and CSL/bioCSL, with MedImmune's live-attenuated FluMist as the only intranasal option. PowderMed's particle-mediated epidermal delivery (PMED) platform fired DNA-coated gold microparticles into the epidermis with pressurized helium, aiming to bypass needles, shorten manufacturing timelines, and elicit both antibody and cell-mediated responses. Pipeline candidates included a Phase II seasonal flu DNA vaccine, plus Phase I assets for HSV and chronic hepatitis B and a preclinical genital warts program (Pharmafile, 2006). Pfizer at the time had no human vaccine franchise, so the deal was framed as both a flu/pandemic preparedness play and a beachhead into vaccines ahead of the eventual 2009 Wyeth acquisition (which delivered Prevnar). Estimated value of roughly $400M (Chemical & Engineering News, Oct 2006) implied Pfizer was paying primarily for the PMED platform and pandemic optionality rather than near-term revenue, since no PowderMed product ever reached approval and Pfizer ultimately wound the platform down.